Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 418

1.
2.

From clinical research to clinical practice: a 4-year review of ziprasidone.

Nemeroff CB, Lieberman JA, Weiden PJ, Harvey PD, Newcomer JW, Schatzberg AF, Kilts CD, Daniel DG.

CNS Spectr. 2005 Nov;10(11 Suppl 17):1-20.

PMID:
16381088
3.

Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia.

Stimmel GL, Gutierrez MA, Lee V.

Clin Ther. 2002 Jan;24(1):21-37. Review.

PMID:
11833834
4.

Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic.

Daniel DG, Copeland LF.

Expert Opin Investig Drugs. 2000 Apr;9(4):819-28. Review.

PMID:
11060712
5.

Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.

Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA 3rd, et al.

J Pharmacol Exp Ther. 1995 Oct;275(1):101-13.

PMID:
7562537
6.

Tolerability of ziprasidone: an expanding perspective.

Daniel DG.

J Clin Psychiatry. 2003;64 Suppl 19:40-9. Review.

7.

Ziprasidone: the fifth atypical antipsychotic.

Caley CF, Cooper CK.

Ann Pharmacother. 2002 May;36(5):839-51. Review.

PMID:
11978164
8.

Maintaining symptom control: review of ziprasidone long-term efficacy data.

Schooler NR.

J Clin Psychiatry. 2003;64 Suppl 19:26-32. Review.

9.

Ziprasidone: a new atypical antipsychotic.

Keck PE Jr, McElroy SL, Arnold LM.

Expert Opin Pharmacother. 2001 Jun;2(6):1033-42. Review.

PMID:
11585006
10.

Serotonin receptors: their key role in drugs to treat schizophrenia.

Meltzer HY, Li Z, Kaneda Y, Ichikawa J.

Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72. Review.

PMID:
14642974
11.

Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials.

Kane JM.

J Clin Psychiatry. 2003;64 Suppl 19:19-25. Review.

12.
13.

Ziprasidone: profile on safety.

Goodnick PJ.

Expert Opin Pharmacother. 2001 Oct;2(10):1655-62. Review.

PMID:
11825308
14.

Focus on ziprasidone.

Green B.

Curr Med Res Opin. 2001;17(2):146-50. Review.

PMID:
11759185
15.

Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials.

Greenberg WM, Citrome L.

CNS Drug Rev. 2007 Summer;13(2):137-77. Review.

16.

Atypical antipsychotics: mechanism of action.

Seeman P.

Can J Psychiatry. 2002 Feb;47(1):27-38. Review.

PMID:
11873706
17.

Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.

Bishara D, Taylor D.

Drugs. 2008;68(16):2269-92. doi: 10.2165/0003495-200868160-00002. Review.

PMID:
18973393
18.

Using antipsychotic agents in older patients.

Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients.

J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. Review.

19.

Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade.

Wood MD, Scott C, Clarke K, Cato KJ, Patel N, Heath J, Worby A, Gordon L, Campbell L, Riley G, Davies CH, Gribble A, Jones DN.

CNS Neurol Disord Drug Targets. 2006 Aug;5(4):445-52.

PMID:
16918396
20.

Receptor mechanisms in the treatment of schizophrenia.

Reynolds GP.

J Psychopharmacol. 2004 Sep;18(3):340-5. Review.

PMID:
15358977
Items per page

Supplemental Content

Write to the Help Desk